ANI Pharmaceuticals, Inc.
ANIP
$67.24
-$0.125-0.19%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 486.82M | 449.39M | 401.39M | 358.69M | 316.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 486.82M | 449.39M | 401.39M | 358.69M | 316.39M |
| Cost of Revenue | 181.51M | 164.42M | 149.21M | 141.22M | 137.79M |
| Gross Profit | 305.30M | 284.98M | 252.17M | 217.47M | 178.60M |
| SG&A Expenses | 161.70M | 141.02M | 129.10M | 122.30M | 114.64M |
| Depreciation & Amortization | 59.79M | 59.08M | 58.04M | 57.12M | 56.97M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 437.29M | 394.16M | 362.53M | 343.60M | 331.72M |
| Operating Income | 49.53M | 55.23M | 38.86M | 15.09M | -15.33M |
| Income Before Tax | 19.87M | 13.20M | -10.54M | -34.60M | -62.67M |
| Income Tax Expenses | 1.09M | -184.00K | -5.38M | -8.28M | -14.77M |
| Earnings from Continuing Operations | 18.78 | 13.38 | -5.16 | -26.33 | -47.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.78M | 13.38M | -5.16M | -26.33M | -47.90M |
| EBIT | 49.53M | 55.23M | 38.86M | 15.09M | -15.33M |
| EBITDA | 109.32M | 115.40M | 99.17M | 74.89M | 44.32M |
| EPS Basic | 0.85 | 0.53 | -0.48 | -1.72 | -3.05 |
| Normalized Basic EPS | 0.88 | 1.03 | 0.42 | -0.43 | -1.56 |
| EPS Diluted | 0.84 | 0.51 | -0.50 | -1.73 | -3.06 |
| Normalized Diluted EPS | 0.87 | 1.02 | 0.42 | -0.43 | -1.56 |
| Average Basic Shares Outstanding | 71.97M | 69.29M | 66.71M | 65.29M | 65.04M |
| Average Diluted Shares Outstanding | 72.73M | 69.84M | 67.01M | 65.43M | 65.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | 8.65% | 12.15% | -31.52% | -6.18% | -3.39% |
